Regeneron Pharmaceuticals, Inc.

Valuation Analysis

About the Company

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoi

Regeneron Pharmaceuticals, Inc. Stock at a Glance

Regeneron Pharmaceuticals, Inc. (REGN) is currently trading at $612.14 with a market capitalization of $64.2B. The trailing P/E ratio stands at 14.95x, with a forward P/E of 11.38x. The 52-week range spans from $503.25 to $821.11; the current price is 25.4% below the yearly high. Year-over-year revenue growth stands at +19.0%. The net profit margin stands at 29.65%.

💰 Dividend

Regeneron Pharmaceuticals, Inc. pays an annual dividend of $3.76 per share, representing a yield of 0.61%. The payout ratio stands at 8.74%.

📊 Analyst Rating

28 analysts rate Regeneron Pharmaceuticals, Inc. (REGN) on consensus: Buy. The average price target is $833.31, implying +36.13% from the current price. Analyst price targets range from $641.00 to $1,000.00.

Regeneron Pharmaceuticals, Inc.: The Investment Case in Detail

Regeneron Pharmaceuticals, Inc. (REGN) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 19% pace year-over-year, suggesting the business model continues to find new customers and pricing power. The combination of a 43.89% gross margin and 20.66% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Free cash flow is positive and net margins stand at 29.65%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Valuation in Context

The PEG ratio at 1.07 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 11.38x is meaningfully below the trailing 14.95x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 36.13% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Regeneron Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.